THERADIAG secures a standby equity facility (SEF®) with Société Générale Business Wire CROISSY-BEAUBOURG, France & MONTPELLIER, France -- April 16, 2014 Regulatory News: Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces that it has set up a standby equity facility (SEF®) with Société Générale, as approved by shareholders at the Annual General Meeting of April 8, 2014. “We have entered into an active phase for the commercial development of our innovative products in France and internationally, and we want to insure that we have the financial means to support our ambitions,” comments Michel Finance, CEO of Theradiag. “This standby equity facility strengthens our financial flexibility and diversifies our sources of financing, while preserving our financial structure thanks to a limited discount. The funds raised will notably allow us to strengthen the development of our theranostics portfolio in the United States.” At Theradiag’s request, Société Générale is committed to subscribe to successive capital increases, issued by tranches over the next 24 months, within the global limit of 445,000 shares, i.e. 9.9% of the number of shares currently outstanding^1. For each tranche, the issuance price will reflect the volume-weighted average price of shares for the three trading days immediately preceding the issue date, minus a discount of nomorethan 5%. This discount will enable Société Générale to instantly underwrite the shares despite possible market volatility. Acting as financial intermediary, Société Générale has no intention to remain a shareholder of the Company. Should the entire standby equity facilty be drawn^2, a shareholder currently owning 1.0% of the company’s share capital would see his or her share ownership reduced to 0.91%^3. About Theradiag Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 60 employees. For more information about Theradiag, please visit our website: www.theradiag.com ^1 4,473,150 shares currently outstanding ^2 Leading to the issuance of 445,000 new shares ^3 Based on the non-fully diluted number of shares currently outstanding Contact: Theradiag Investor Relations Nathalie Trepo, +33 1 64 62 10 12 firstname.lastname@example.org or NewCap. Financial communications/ investor relations Valentine Brouchot / Pierre Laurent, +33 1 44 71 94 94 email@example.com or Alize RP Press Caroline Carmagnol, +33 6 64 18 99 59 firstname.lastname@example.org
THERADIAG secures a standby equity facility (SEF®) with Société Générale
Press spacebar to pause and continue. Press esc to stop.